How have PLSE shares performed in 2024?

Pulse Biosciences' stock was trading at $12.24 at the beginning of the year. Since then, PLSE shares have decreased by 39.0% and is now trading at $7.47. View the best growth stocks for 2024 here .

When is Pulse Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our PLSE earnings forecast .

How were Pulse Biosciences' earnings last quarter?

Pulse Biosciences, Inc. (NASDAQ:PLSE) posted its quarterly earnings results on Thursday, March, 30th. The company reported ($0.24) EPS for the quarter. The company had revenue of ($0.01) million for the quarter.

What is Darrin R. Uecker's approval rating as Pulse Biosciences' CEO?

2 employees have rated Pulse Biosciences Chief Executive Officer Darrin R. Uecker on Glassdoor.com . Darrin R. Uecker has an approval rating of 100% among the company's employees. This puts Darrin R. Uecker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pulse Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulse Biosciences investors own include Advanced Micro Devices (AMD) , AbbVie (ABBV) , Bausch Health Companies (BHC) , Wayfair (W) , Achaogen (AKAO) , NVIDIA (NVDA) , Portola Pharmaceuticals (PTLA) , Enphase Energy (ENPH) and Novavax (NVAX) .

When did Pulse Biosciences IPO?

Pulse Biosciences (PLSE) raised $20 million in an initial public offering (IPO) on Wednesday, May 18th 2016. The company issued 5,000,000 shares at a price of $4.00 per share. MDB Capital Group and Feltl and Company served as the underwriters for the IPO.

Who are Pulse Biosciences' major shareholders?

Pulse Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Griffin Asset Management Inc. (0.54%). Insiders that own company stock include Kevin Patrick Danahy, Mitchell E Levinson and Robert W Duggan. View institutional ownership trends .

How do I buy shares of Pulse Biosciences?

Shares of PLSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PLSE

Pulse Biosciences (PLSE) Stock Price, News & Analysis

→ Top 5 Tech Stocks to Buy for 2024 (From Daily Market Alerts) (Ad)

Free PLSE Stock Alerts

$7.47

-0.31 (-3.98%)

(As of 04/17/2024 ET)

Compare

Today's Range: $7.38
▼
$7.87
50-Day Range: $7.22
▼
$10.88
52-Week Range: $3.78
▼
$13.62

Volume: 149,671 shs
Average Volume: 184,985 shs
Market Capitalization: $412.49 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Pulse Biosciences alerts:

Ad Crypto 101 Media

[Urgent!] Generational Wealth Gameplan

A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.

Click here to get instant access to the guide

About Pulse Biosciences Stock (NASDAQ:PLSE)

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

PLSE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PLSE Stock News Headlines

April 13, 2024 | americanbankingnews.com

Pulse Biosciences (NASDAQ:PLSE) Stock Crosses Below 50 Day Moving Average of $8.98

March 29, 2024 | finance.yahoo.com

Q4 2023 Pulse Biosciences Inc Earnings Call

April 18, 2024 | Timothy Sykes (Ad)

Urgent alert: open this for a huge profit potential

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

March 28, 2024 | investorplace.com

PLSE Stock Earnings: Pulse Biosciences Reported Results for Q4 2023

March 28, 2024 | finance.yahoo.com

Pulse Biosciences Inc (PLSE) Reports Increased GAAP Costs and Narrowed Net Loss in 2023

March 28, 2024 | businesswire.com

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results

March 28, 2024 | businesswire.com

Pulse Biosciences Announces Plans to Initiate a Rights Offering

March 17, 2024 | finance.yahoo.com

PLSE Apr 2024 25.000 call

April 18, 2024 | Timothy Sykes (Ad)

Urgent alert: open this for a huge profit potential

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

March 17, 2024 | finance.yahoo.com

PLSE Oct 2024 17.500 call

March 16, 2024 | finance.yahoo.com

PLSE Oct 2024 12.500 call

March 16, 2024 | finance.yahoo.com

PLSE Jul 2024 2.500 put

March 14, 2024 | businesswire.com

Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024

March 13, 2024 | msn.com

Pulse Biosciences’s CellFXnsPFA system secures FDA 510(k) clearance

March 10, 2024 | investing.com

FDA clears Pulse Biosciences' soft tissue ablation system

March 9, 2024 | markets.businessinsider.com

Pulse Biosciences Gets FDA 510(k) Clearance For CellFX NsPFA Percutaneous Electrode System

March 8, 2024 | stockhouse.com

Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA(TM) Percutaneous Electrode System

March 8, 2024 | businesswire.com

Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System

February 14, 2024 | markets.businessinsider.com

Pulse Biosciences Announces Positive Results For CellFX NsPFA 360 Cardiac Catheter Study; Stock Up

February 14, 2024 | finance.yahoo.com

Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study

February 14, 2024 | businesswire.com

Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study

February 2, 2024 | finance.yahoo.com

Companies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In Growth

January 31, 2024 | finance.yahoo.com

Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium

January 6, 2024 | finance.yahoo.com

Insiders of Pulse Biosciences, Inc. (NASDAQ:PLSE) must be disappointed as stock fell 26% after recent purchases

January 2, 2024 | finance.yahoo.com

Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp

December 20, 2023 | finance.yahoo.com

Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter

December 5, 2023 | msn.com

Pulse Biosciences director Duggan buys shares worth $1.4M - filing

See More Headlines

Receive PLSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulse Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/30/2023
Today: 4/17/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:PLSE
CUSIP: N/A
CIK: 1625101
Web: www.pulsebiosciences.com
Phone: (510) 906-4600
Fax: N/A
Employees: 61
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.89)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-42,210,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -112.74%
Return on Assets: -61.09%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.76
Quick Ratio: 6.76

Sales & Book Value

Annual Sales: $700,000.00
Price / Sales: 589.28
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.81 per share
Price / Book: 9.22

Miscellaneous

Outstanding Shares: 55,220,000
Free Float: 16,733,000
Market Cap: $412.49 million
Optionable: Optionable
Beta: 1.67

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Robert W. Duggan (Age 79)
Executive Chairman
Mr. Kevin P. Danahy (Age 52)
President & CEO
Comp: $834.73k
Mr. Darrin R. Uecker (Age 58)
CTO & Director
Comp: $834.73k
Mr. Mitchell E. Levinson (Age 64)
Chief Strategy Officer
Comp: $584.57k
Dr. Richard Nuccitelli Ph.D.
Chief Science Officer
Mr. Kenneth B. Stratton Esq. (Age 55)
J.D., General Counsel & Corporate Secretary
Ms. Patty Perla
Vice President of Human Resources
Mr. David Danitz
Senior Vice President of Engineering
Dr. Gansevoort Dunnington M.D.
Chief Medical Officer
Dr. Niv Ad M.D.
Chief Science Officer of Cardiac Surgery

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PLSE Stock Analysis - Frequently Asked Questions

How have PLSE shares performed in 2024?: Pulse Biosciences' stock was trading at $12.24 at the beginning of the year. Since then, PLSE shares have decreased by 39.0% and is now trading at $7.47.
View the best growth stocks for 2024 here.
When is Pulse Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our PLSE earnings forecast.
How were Pulse Biosciences' earnings last quarter?: Pulse Biosciences, Inc. (NASDAQ:PLSE) posted its quarterly earnings results on Thursday, March, 30th. The company reported ($0.24) EPS for the quarter. The company had revenue of ($0.01) million for the quarter.
What is Darrin R. Uecker's approval rating as Pulse Biosciences' CEO?: 2 employees have rated Pulse Biosciences Chief Executive Officer Darrin R. Uecker on Glassdoor.com. Darrin R. Uecker has an approval rating of 100% among the company's employees. This puts Darrin R. Uecker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pulse Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Pulse Biosciences investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Bausch Health Companies (BHC), Wayfair (W), Achaogen (AKAO), NVIDIA (NVDA), Portola Pharmaceuticals (PTLA), Enphase Energy (ENPH) and Novavax (NVAX).
When did Pulse Biosciences IPO?: Pulse Biosciences (PLSE) raised $20 million in an initial public offering (IPO) on Wednesday, May 18th 2016. The company issued 5,000,000 shares at a price of $4.00 per share. MDB Capital Group and Feltl and Company served as the underwriters for the IPO.
Who are Pulse Biosciences' major shareholders?: Pulse Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Griffin Asset Management Inc. (0.54%). Insiders that own company stock include Kevin Patrick Danahy, Mitchell E Levinson and Robert W Duggan.
View institutional ownership trends.
How do I buy shares of Pulse Biosciences?: Shares of PLSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PLSE) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial